One interesting observation from the combination of TRAIL studies reveals that inhibition of B-RAF/MEK/ERK signaling actually decreases DR5 in melanoma cells, preventing or attenuating apoptosis induced by TRAIL, agonistic antibody against DR5, or T cells [48]. Here, BRAF is linked to melanoma.